View a conversation with Dr. Ledford Powell about the effectiveness of the Prevenio™ Lung RS Test.
In 2012, Life Technologies launched Pervenio™ Lung RS, a Risk Stratification Test for early stage lung cancer. Diagnostic reliably identifies patients at high risk for mortality and fulfills an unmet need for prognostic data to better manage lung cancer.
– Accurate and Reliable Risk Stratification of Early-Stage Patients for Better-Informed Decisions Regarding Potentially Life Saving Interventions
– 14-Gene qPCR Assay Validated in Approximately 1,500 Patients, Results Published in The Lancet
– Offered through Life Technologies’ CLIA Laboratory Developed Test Service